Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H26N8 |
| Molecular Weight | 426.5168 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CCC1=NC2=C(N1)C=CC(=C2)C3=NCCN3)CC4=NC5=C(N4)C=C(C=C5)C6=NCCN6
InChI
InChIKey=HSOKEDVIVDSCPU-UHFFFAOYSA-N
InChI=1S/C24H26N8/c1(3-21-29-17-7-5-15(13-19(17)31-21)23-25-9-10-26-23)2-4-22-30-18-8-6-16(14-20(18)32-22)24-27-11-12-28-24/h5-8,13-14H,1-4,9-12H2,(H,25,26)(H,27,28)(H,29,31)(H,30,32)
| Molecular Formula | C24H26N8 |
| Molecular Weight | 426.5168 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8215291
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8215291
1,4-BIS(5-(2-IMIDAZOLINYL)-2-BENZIMIDAZOLYL)BUTANE is a dicationically substituted bis-benzimidazole, which was found to be more potent and less toxic than pentamidine in the rat model of Pneumocystis carinii pneumonia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pentamidine is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 receptors. | 1999-06-21 |
|
| New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. | 1995-11-24 |
|
| Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. | 1994-09 |
|
| Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. | 1993-08 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8215291
Rats: 1,4-BIS(5-(2-IMIDAZOLINYL)-2-BENZIMIDAZOLYL)BUTANE showed excellent activity down to a dose of 2.5 mg/kg/day and produced a significant reduction, compared with the saline control group, in the number of cysts per gram of lung tissue at a dose of 1 mg/kg/day. A compound showed no overt toxicity when administered at 15mg/kg/day for 14 days.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:52:06 GMT 2025
by
admin
on
Mon Mar 31 21:52:06 GMT 2025
|
| Record UNII |
A9K12S2G4K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
456606
Created by
admin on Mon Mar 31 21:52:06 GMT 2025 , Edited by admin on Mon Mar 31 21:52:06 GMT 2025
|
PRIMARY | |||
|
DTXSID50933394
Created by
admin on Mon Mar 31 21:52:06 GMT 2025 , Edited by admin on Mon Mar 31 21:52:06 GMT 2025
|
PRIMARY | |||
|
A9K12S2G4K
Created by
admin on Mon Mar 31 21:52:06 GMT 2025 , Edited by admin on Mon Mar 31 21:52:06 GMT 2025
|
PRIMARY | |||
|
148344-24-5
Created by
admin on Mon Mar 31 21:52:06 GMT 2025 , Edited by admin on Mon Mar 31 21:52:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |